Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study

PURPOSE: The WSG-PRIMe Study prospectively evaluated the impact of the 70-gene signature MammaPrint® (MP) and the 80-gene molecular subtyping assay BluePrint® on clinical therapy decisions in luminal early breast cancer. METHODS: 452 hormone receptor (HR)-positive and HER2-negative patients were rec...

Descripción completa

Detalles Bibliográficos
Autores principales: Wuerstlein, R., Kates, R., Gluz, O., Grischke, E. M., Schem, C., Thill, M., Hasmueller, S., Köhler, A., Otremba, B., Griesinger, F., Schindlbeck, C., Trojan, A., Otto, F., Knauer, M., Pusch, R., Harbeck, N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2019
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6533223/
https://www.ncbi.nlm.nih.gov/pubmed/30796651
http://dx.doi.org/10.1007/s10549-018-05075-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6533223/
https://www.ncbi.nlm.nih.gov/pubmed/30796651
http://dx.doi.org/10.1007/s10549-018-05075-x

Ejemplares similares